- CEO
- Han Xiong Li
- Full Time Employees
- 1,294
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 27, Yunrun Building Guangzhou GD China 510320
- IPO Date
- Nov 16, 2017
- Business
- ApicHope Pharmaceutical Group Co., Ltd. (300723.SZ) engages in the research, development, production and sale of pharmaceutical drugs primarily in China, with a focus on pediatrics and chronic disease medications; its core products include pediatric medicines such as Fuganlin oral liquid, Yiqi Jianpi oral liquid, Carboxymestrine oral solution, Xiao'er Kechuanling oral liquid, Clindamycin Palmitate Hydrochloride dispersible tablets, Acetylkitasamycin for suspension and Qinxiangqingjie oral liquid; chronic disease drugs comprise hepatocyte growth stimulating hormone and pentoxifylline for injections, Kangshen granules, Uqingshu granules, Shenbai lotion, compound monoammonium glycyrrhizinate S and lansoprazole for injections, and Houttuynia sodium; additional offerings cover anti-infection, cardiovascular, genitourinary, respiratory, liver and digestion, dermatological, anti-inflammatory and analgesic products, alongside innovative pharmaceuticals and vaccines. Founded in 2002 and headquartered in Guangzhou, China, the company operates through the full pharmaceutical industry chain, including subsidiaries like Guangzhou Redbud Pharmaceutical Co., Ltd., and maintains production facilities recognized as a National Green Factory and 2024 Guangdong Provincial Manufacturing Single Champion Enterprise. In December 2024, it changed its name from ApicHope Pharmaceutical Co., Ltd. to ApicHope Pharmaceutical Group Co., Ltd.; recent developments include its wholly-owned subsidiary obtaining clinical trial approval for Fuganlin Granules, approval for compound polyethylene glycol (3350) electrolyte dispersion registration certificate, and a new drug clinical trial nod for an endometriosis treatment, alongside ongoing partnerships such as the joint venture with Arthrosi Therapeutics via Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. to advance AR882 for gout and AR035 for oncology in Greater China.